STARLITE 2: Phase 2 study of nivolumab plus (177)lutetium-labeled anti-carbonic anhydrase IX (CAIX) monoclonal antibody girentuximab ((177)Lu-girentuximab) in patients with advanced clear cell renal cell carcinoma (ccRCC) Meeting Abstract

  

Authors:	Feldman, D. R.; Motzer, R. J.; Knezevic, A.; Voss, M. H.; Lyashchenko, S. K.; Park, H.; Larson, S. M.; Pandit-Taskar, N.
Abstract Title:	STARLITE 2: Phase 2 study of nivolumab plus (177)lutetium-labeled anti-carbonic anhydrase IX (CAIX) monoclonal antibody girentuximab ((177)Lu-girentuximab) in patients with advanced clear cell renal cell carcinoma (ccRCC)
Meeting Title:	2025 ASCO Genitourinary Cancers Symposium
Journal Title:	Journal of Clinical Oncology
Volume:	43
Issue:	5 Suppl.
Meeting Dates:	2025 Feb 13-15
Meeting Location:	San Francisco, CA
ISSN:	0732-183X
Publisher:	American Society of Clinical Oncology
Date Published:	2025-02-10
Language:	English
ACCESSION:	WOS:001454744100003
DOI:	10.1200/JCO.2025.43.5_suppl.TPS608
PROVIDER:	wos
Notes:	Meeting Abstract: TPS608 -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/225322